Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (492)	8/25/1999 11:18:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 717

Thanks, squetch. Presumably these 23 patients included the cohorts with the initial (low) drug and light doses, and efficacy will likely improve further as they get to higher doses. Don't know if these patients overlap the original 14 that were reported, of which 12 responded. From the prior release: The phase I trial enrolled 50 patients with symptomatic atherosclerosis involving the major arteries of the lower extremities. The two-part study was designed to first, establish an optimum dose of ANTRIN by treating successive cohorts of patients with increasing single doses of the drug. In the second part of the study, three doses of light were evaluated at several drug dose levels. <snip> Using IVUS, it was reported that 12 of 14 evaluable patients responded to treatment, defined as an increase of greater than 10% in the blood vessel opening or minimal luminal diameter (MLD). Responding patients had increases in MLD up to 76% with a mean of 35%. I assume we'll get more details when they make the presentation. I liked that "strongly suggest" in the conclusion. <g> Peter